Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 526 to 540 of 546 results for iv

  1. Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (TA127)

    Evidence-based recommendations on natalizumab (Tysabri) for treating highly active relapsing–remitting multiple sclerosis in adults.

  2. Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (TA119)

    Evidence-based recommendations on fludarabine monotherapy for untreated chronic lymphocytic leukaemia in adults.

  3. Palliative photodynamic therapy for advanced oesophageal cancer (IPG206)

    Evidence-based recommendations on palliative photodynamic therapy for treating advanced oesophageal cancer. This involves injecting a photosensitising agent into the tumour and using light to activate it and destroy the tumour cells.

  4. Gemcitabine for the treatment of metastatic breast cancer (TA116)

    Evidence-based recommendations on gemcitabine for treating metastatic breast cancer in adults.

  5. Photodynamic therapy for early-stage oesophageal cancer (IPG200)

    Evidence-based recommendations on photodynamic therapy for early-stage oesophageal cancer. This involves injecting a photosensitising agent into the tumour which is then activated by a light to destroy the tumour cells.

  6. Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer (TA100)

    Evidence-based recommendations on capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer in adults.

  7. Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)

    Evidence-based recommendations on paclitaxel for treating ovarian cancer in adults.

  8. Photodynamic therapy for advanced bronchial carcinoma (IPG87)

    Evidence-based recommendations on photodynamic therapy for advanced bronchial carcinoma. This involves giving the patient something that makes them sensitive to light, then using special equipment to shine light onto the cancer to activate the substance and destroy some of the cancer.

  9. Pre-hospital initiation of fluid replacement therapy in trauma (TA74)

    Evidence-based recommendations on giving intravenous (IV) fluid replacement therapy for people with serious injuries before reaching hospital.

  10. Magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids (IPG30)

    Evidence-based recommendations on magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids. This involves passing laser heat through needles inserted into the fibroid to destroy it.

  11. Radiofrequency ablation of varicose veins (IPG8)

    Evidence-based recommendations on radiofrequency ablation of varicose veins. This involves using radiofrequency energy to heat the wall of the vein so that it collapses.

  12. Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)

    Evidence-based recommendations on capecitabine for treating metastatic colorectal cancer in adults.

  13. Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction (TA52)

    Evidence-based recommendations on using thrombolytic drugs (alteplase [Actilyse], reteplase [Rapilysin], streptokinase [Streptase] and tenecteplase [Metalyse]) for treating acute myocardial infarction in adults.

  14. Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)

    Evidence-based recommendations on fludarabine (Fludara) for B-cell chronic lymphocytic leukaemia.

  15. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued [GID-TAG479]